# Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Source: https://onco.cc/trials/nct01020448/  
OnCo record `nct01020448` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Triptorelin in Prostate cancer, run by Ipsen, completed.

## Summary

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01020448 by Ipsen, with 339 participants recorded, started 2009-11 and reaching its primary completion in 2011-11. Interventions recorded: Triptorelin (Decapeptyl®). Conditions recorded: Prostate Cancer.

Linked to the drug Triptorelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01020448
- Phase: 3
- Setting: Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study
- Sponsor: Ipsen
- Enrolled: 339

## Sources

- ClinicalTrials.gov NCT01020448: https://clinicaltrials.gov/study/NCT01020448

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Triptorelin](https://onco.cc/drugs/triptorelin/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)

---
JSON: https://onco.cc/api/v1/entities/nct01020448.json